Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2025 ...

Merck (known as MSD outside of the United States and Canada) will complete its $9.2 billion acquisition of Cidara ...

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

Merck (known as MSD outside the US) has announced an agreement with the US government to provide key products to patients at ...

CAMBRIDGE, England--(BUSINESS WIRE)--Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, today announces it has entered into a clinical trial ...

Commits $1.5 Billion to R&D in China Over The Next 5 Years WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., (NYSE:MRK), known as MSD outside the United States and Canada, today announced ...

• Court says MSD breached an agreement with Merck KGaA, Darmstadt, Germany in the UK by using "Merck" alone either as a trade mark or a name Darmstadt, Germany, January 15, 2016 – Merck KGaA, ...

Lundbeck and Merck sign exclusive commercialisation agreement for SYCREST® (asenapine) sublingual tablets in all markets outside of the United States, China and Japan Release date: 12-10-2010 SYCREST® ...